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ABSTRACT: The muscarinic M1 acetylcholine receptor is an important drug target for
the treatment of various neurological disorders. Designing M1 receptor-selective drugs
has proven challenging, mainly due to the high conservation of the acetylcholine
binding site among muscarinic receptor subtypes. Therefore, less conserved and
topographically distinct allosteric binding sites have been explored to increase M1
receptor selectivity. In this line, bitopic ligands, which target orthosteric and allosteric
binding sites simultaneously, may provide a promising strategy. Here, we explore the
allosteric, M1-selective BQCAd scaffold derived from BQCA as a starting point for the
design, synthesis, and pharmacological evaluation of a series of novel bitopic ligands in
which the orthosteric moieties and linker lengths are systematically varied. Since β-
arrestin recruitment seems to be favorable to therapeutic implication, all the compounds
were investigated by G protein and β-arrestin assays. Some bitopic ligands are partial to
full agonists for G protein activation, some activate β-arrestin recruitment, and the
degree of β-arrestin recruitment varies according to the respective modification. The
allosteric BQCAd scaffold controls the positioning of the orthosteric ammonium group of all ligands, suggesting that this interaction
is essential for stimulating G protein activation. However, β-arrestin recruitment is not affected. The novel set of bitopic ligands may
constitute a toolbox to study the requirements of β-arrestin recruitment during ligand design for therapeutic usage.
■ INTRODUCTION
Muscarinic acetylcholine receptors belong to the superfamily
of G protein-coupled receptors. Five muscarinic receptor
subtypes (M1−M5) are expressed in humans and mediate a
variety of physiological functions.1,2 The binding site for the
endogenous neurotransmitter acetylcholine, classical synthetic
orthosteric agonists (e.g., carbachol, oxotremorine, oxotremor-
ine-M, and iperoxo), and antagonists (e.g., atropine, N-
methylscopolamine, and ipratropium) is located deeply inside
the seven-fold transmembrane helical bundle.3,4 All muscarinic
receptor subtypes share a high sequence similarity in their
orthosteric binding pockets, which has entailed severe
difficulties in the discovery of subtype-selective ligands for
this receptor family.4−6 Moreover, all muscarinic receptors
possess at least one allosteric binding site, which is located on
top of the orthosteric binding site comprising the upper parts
of transmembrane helices and extracellular loops.7−10
M1 muscarinic receptors are predominantly expressed in the
central nervous system (CNS), especially in the amygdala,
hippocampus, cerebral cortex, and striatum11,12 where they
contribute to essential cognitive functions such as memory and
learning. The M1 muscarinic receptor has been identified as an
important drug target, which may be addressed for the
treatment of Alzheimer’s disease (AD) and schizophrenia.13,14
Although activation of M1 receptors with synthetic orthosteric
agonists has been shown to be effective in a variety of CNS
diseases,15−17 all ligands exhibited severe adverse effects, which
have eventually led to withdrawal from drug discovery
programs, likely due to missing subtype selectivity of these
drug candidates.18,19
New strategies for obtaining more selective ligands have
been explored by either using positive allosteric modulators
(PAMs)20−26 or by structural hybrids of orthosteric and
allosteric moieties. These latter so-called bitopic ligands have
been originally developed based upon the hypothesis of
combining the activation properties of orthosteric ligands with
the better selectivity profile of allosteric ligands.24,27−29 A
number of studies have lately shown that through the design of
bitopic ligand series, a differential engagement of all possible
GPCR signaling pathways can be studied.30,31 We have
previously synthesized bitopic agonists for the M1 receptor
(Scheme 1, 1-Cn), which consist of the orthosteric agonists
iperoxo or acetylcholine and the M1R-selective positive
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allosteric modulators (PAM) BQCAd.32−36 Benzyl quinolone
carboxylic acid (BQCA) and its derivatives were reported
being positive allosteric modulators (PAMs). Compared to
their orthosteric counterparts, they confer a high selectivity in
terms of binding and function at M1 receptors.33,37 Underlying
structure−activity relationship studies suggested that the
potency and efficacy of bitopic agonists basically depend on
three substantial factors, i.e., linker length, geometry of the
position of orthosteric and allosteric moieties, as well as the
substitution pattern of the allosteric moiety.37−39
Here, we introduce a systematic set of novel bitopic ligands
for the M1 receptor, which were designed by connecting the
allosteric moiety BQCAd to orthosteric muscarinic agonists
using methylene linkers of varying length (Scheme 1). The
allosteric interaction of BQCAd is shown in the Supporting
Information (Table S4 and Figure S1 (panel F)). Classical
orthosteric agonists were chosen as building blocks of the
bitopic ligands aiming at a comparison of a myriad of study
results from the literature and obtaining a deepened under-
standing of previously published works.37,38 In order to derive
structure−activity relationships, the set of compounds was
tested for the ability to activate G protein signaling and β-
arrestin recruitment. Our data show that efficacy and potency
of bitopic ligands strongly depend on the structure of the
orthosteric moiety, which is supported by respective docking
studies. The smallest known muscarinic agonist, tetramethy-
lammonium (TMA),40,41 has a sufficient efficacy to activate G
proteins but is not suitable for recruiting β-arrestin.
Interestingly, the iperoxo hybrids 1-C6 and 1-C8 as well as
the isoxo ligand 3-C8 were able to recruit β-arrestin2. Of note,
our data demonstrates how subtle differences in ligand
structure can impact receptor activation and simultaneously
suggests that different regions of the orthosteric binding site
can be explored in order to investigate M1 receptor signaling.
■ RESULTS AND DISCUSSION
Chemistry. Compounds 1-Cn, 2-Cn, and 5-Cn were
prepared according to previously reported procedures.37,38
Compound series 3-Cn and 4-Cn and their overall synthetic
pathways are displayed in Scheme 1 (for further details, see
Supporting Information Data S1). The 4-oxo-quinoline
skeleton was built up using the Gould−Jacobs synthetic
procedure using diethyl 2-(ethoxymethylene)-malonate for
condensation with 4-fluoroaniline followed by cyclization in
Scheme 1. Synthetic Pathway of the Bitopic M1 Receptor Ligands Composed of the PAM Benzyl Quinolone Carboxylic Acid
Derivative (BQCAd 6) Covalently Linked to Non-selective Muscarinic Orthosteric Agonist Fragments (Iperoxo 1,
Acetylcholine 2, Isoxo 3, Oxotremorine-M 4, and TMA (Tetramethylammonium) Head 5)a
aReagents and conditions: (i) benzyl chloride, K2CO3, DMF, and 80 °C; (ii) 6 N HCl, MeOH, and reflux; (iii) H2N(CH2)nOH and 150 °C; (iv)
HBr (48%), H2SO4 and reflux; (v) iperoxo base, KI/K2CO3, CH3CN, and 80 °C MW; (vi) acetylcholine, KI/K2CO3, CH3CN, and 80 °C MW;
(vii) isoxo base, KI/K2CO3, CH3CN, and 80 °C MW; (viii) oxotremorine-M base, KI/K2CO3, CH3CN, and 80 °C MW; (ix) trimethylamine,
CH3CN, and 40 °C.
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diphenyl ether.42−44 Both synthetic procedures were carried
out under microwave assistance to promote conversion and to
achieve better yields. The quinolone nitrogen was benzylated
followed by amidation of the ester function utilizing an
aminoalkyl alcohol of the respective spacer length. Finally, the
hydroxyl function was replaced by a bromine atom using
hydrobromic acid and sulfuric acid.38
All orthosteric fragments were synthesized according to the
literature45−48 to obtain the tertiary base, which was
subsequently used within the final synthesis step yielding the
desired bitopic compounds. In brief, the synthesis of the
isoxazole moiety45 starts with treating methyl propiolate with
commercial hydroxylamine hydrochloride followed by sub-
sequent reaction with 1,4-dichloro-2-butyne. The tertiary base
was finally obtained by adding a two-fold excess of a solution of
dimethylamine in DMF at room temperature requiring a three-
step synthesis. Oxotremorine-M was obtained by starting from
commercially available 2-pyrrolidinone and propargyl bromide
Figure 1. Concentration-response curves in Gα/PLC-β3 split-luciferase interaction assays in HEK293T cells expressing the human muscarinic M1
receptors (hM1), which were stimulated by utilizing varying concentrations of indicated compounds. Data is expressed as the means ± S.E.M. of
3−6 independent experiments performed in triplicate. The data were normalized to iperoxo (panel A), ACh (panel B), Isoxo (panel C), Oxo-M
(panel D), and carbachol (CCh) (panel E) as a reference (maximum stimulation set to 100%).
Figure 2. Concentration-response curves obtained with a BRET-based assay reporting the recruitment of β-arrestin to M1 receptors stimulated
with various concentrations of indicated compounds (iperoxo-derived bitopic ligands (panel A), ACh-compounds (panel B), isoxazole-bitopic
ligands (panel C), oxotremorine-M based ligands (panel D), and TMA-derived bitopic compounds (panel E)). β-Arrestin recruitment upon
stimulation with saturating concentrations of carbachol (CCh) was set to 100%. Data are normalized to CCh and expressed as the means ± S.E.M.
of 3−6 independent experiments performed in triplicate.
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followed by a CuCl-catalyzed Mannich reaction using
dimethylamine and paraformaldehyde to obtain the corre-
sponding tertiary bases.45,47
The final compounds were obtained by reaction of the
allosteric moiety equipped with the brominated spacer and the
corresponding tertiary orthosteric bases as shown in Scheme 1.
All reactions were conducted using microwave assistance to
shorten reaction times up to 8−48 h. The final compounds
were purified by recrystallization or, in cases where
crystallization was not feasible, by column chromatography
using basic aluminum oxide.
Pharmacology. Recent findings correlate pronounced
cholinergic adverse responses with G protein activation
coupling and phosphorylation-dependent signaling with
maximal clinical efficacy across various AD symptoms.49,50 In
order to evaluate the impact of the orthosteric moieties on
overall ligand activity and to compare the activity of the novel
bitopic compounds with previously studied ones, all ligands
were tested in both G protein signaling and β-arrestin
recruitment assays. As a readout for G protein signaling, we
applied a luminescence-based complementation assay: in intact
cells, the interaction of Gαq with phospholipase Cβ3 being
fused to parts of a luciferase51 can be observed. Upon
stimulation of Gq-coupled receptors, spatial proximity between
Gαq and PLC-β3 allows complementation of the split
luciferase; thus, luminescence derived from a luciferase
substrate is detected. β-Arrestin recruitment was measured
by BRET between a NanoLuc-tagged M1 receptor and β-
arrestin2, N-terminally fused to a Halo tag.37 Moreover, the
ability of the novel ligands to interact with both the orthosteric
and allosteric binding sites was tested in equilibrium and by
applying dissociation binding experiments, respectively (Sup-
porting Information Data S3).
Iperoxo-Derived Bitopic Ligands. Iperoxo is the most
potent and efficacious muscarinic agonist, which has served as
an orthosteric moiety of other bitopic ligands.37,38,52 We
characterized iperoxo-based bitopic ligands with aliphatic
linkers spanning 6 to 10 methylene groups (Scheme 1). Gq/
PLC-β3 complementation assays (Figure 1A) reveal that all
compounds are agonists. 1-C6 and 1-C10 are partial agonists,
whereas 1-C8 behaves as a full agonist for Gq activation.
Increasing the linker length from 6 to 8 methylene groups
increases both potency and efficacy, whereas a further increase
in linker length to 10 methylene groups decreases both
potency and efficacy. The bitopic ligands were tested for their
ability to stimulate β-arrestin recruitment. 1-C6 and 1-C8 are
partial agonists with 1-C6 displaying a slightly higher potency
than 1-C8. 1-C10 fails to stimulate β-arrestin recruitment.
Interestingly, we find that 1-C8 is much more potent and
efficacious than 1-C6 regarding G protein activation (Figure
1A); however, 1-C6 is more potent in recruiting β-arrestin than
1-C8 (Figure 2A).
ACh-Derived Bitopic Ligands. In analogy to the iperoxo-
based compounds, we characterized a set of ACh-derived
bitopic ligands with varying linker lengths ranging from 6 to 10
methylene groups (Scheme 1). All bitopic ligands (2-C6, 2-C8,
and 2-C10) are partial agonists for G protein activation (Figure
1B) and hardly induce any β-arrestin recruitment (Figure 2B).
Only at very high concentrations, i.e., 100 μM, β-arrestin
recruitment can be observed with all three compounds. In line
with iperoxo-derived bitopic ligands (Figure 1A), potency and
efficacy of ACh-based ligands are dependent on linker length.
Increasing the linker length from 6 to 8 (and 10) methylene
groups significantly increases the potency of 1-C8 (and 1-
C10), whereas 1-C10 displays the weakest efficacy of this series
of compounds. The overall efficacy of ACh-derived ligands
appears to be reduced compared to the iperoxo-derived
ligands; however, the structure−activity relationships seem to
be rather similar.
Isoxazole-Derived Bitopic Ligands. Next, we used an
orthosteric agonist, isoxo,46 which is structurally very similar to
iperoxo. The molecule differs by a double bond, which was
introduced into the iperoxo ring system, resulting in an
aromatic isoxazole ring whose influence on the ligand−
receptor interaction was studied. We used isoxo as an
orthosteric fragment to synthesize the bitopic ligands 3-C6,
3-C8, and 3-C10 (Scheme 1). In line with the results obtained
with iperoxo- and ACh-derived bitopic ligands, all isoxo-based
bitopic ligands stimulated G protein activation (Figure 1C).
However, they hardly induced any β-arrestin recruitment
(Figure 2C), which is in line with ACh-based ligands. 3-C8 (a
full agonist) displayed a higher efficacy than 3-C6 (a partial
agonist), whereas 3-C10, in line with aforementioned
observations (Figure 1A,B), demonstrated the weakest potency
and efficacy of the entire series. Full concentration-response
curves for β-arrestin recruitment could not be obtained.
Nevertheless, the data suggest that the activation profile of the
ligands follows that for G protein activation with 3-C8 and 3-
C10 being the most and least efficacious ligands, respectively
(Figure 2C).
Oxotremorine-M-Derived Bitopic Ligands. In the next
set of compounds, another classical non-selective muscarinic
agonist, oxotremorine-M, was used as an orthosteric moiety
giving rise to the series of bitopic ligands 4-C6, 4-C8, and 4-
C10 (Scheme 1). As seen with previous series of bitopic
ligands, increasing the linker length from six to eight methylene
groups seems to yield better agonists. 4-C8 displays a higher
potency and a higher efficacy than 4-C6, whereas a further
increase of the linker length decreases the potency and efficacy
of 4-C10 (Figure 1D). All compounds only weakly stimulate β-
arrestin recruitment at 100 μM and appear to behave similarly
(Figure 2D).
TMA-Derived Bitopic Ligands. Lastly, we used the
smallest muscarinic agonist described in the literature, i.e.,
TMA, as a building block for bitopic ligands. We synthesized
the minimal-size bitopic ligands 5-C6, 5-C8, and 5-C10
(Scheme 1). In line with all previous data, TMA-based ligands
stimulated G protein activation (Figure 1E) in a linker-length
dependent manner. Again, the octamethylene linker (5-C8)
seems to be more favorable for G protein activation than the
hexamethylene linker (5-C6). In contrast to the other series of
bitopic ligands described above, the 5-C10 compound shows a
higher potency than 5-C6 (Figure 1E). Interestingly, all TMA-
based ligands behave as full agonists. The ligand-induced
recruitment of β-arrestin 2, determined by a BRET-based
assay,51 was very weak for the entire series of ligands and could
only be detected for the highest ligand concentration tested
throughout the experiments (100 μM; Figure 2E). Overall,
based on the experimental data, three general observations can
be made: First, the majority of bitopic ligands of the series 1-
Cn to 4-Cn are weaker agonists than their parent orthosteric
agonists; second, all bitopic ligands show negligible to little
efficacy in recruiting β-arrestin; and third, a linker length of
eight methylene groups appears to be optimal for G protein
activation by all bitopic ligands. This is in line with the recent
finding regarding the bitopic agonist iper-8-phth capable of
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binding to and activating the M1 receptor as a full agonist.53
Noteworthy, shortening of the linker to four methylene groups
did not lead to improved G protein activation for the TMA
bitopic ligands neither in terms of maximum response nor in
potency (Supporting Information Figure S4).
Binding Modes of BQCAd-Based Bitopic Ligands. In
order to gain structural insights into binding poses and to link
them to the observed activities, we performed computational
analysis of selected bitopic ligands with focus on the n-C8
series. Docking to the active M1 receptor resulted in plausible
poses for all bitopic ligands. Due to the spatial requirements
and the rigidity of the BQCAd building block, the orientation
of its bitopic derivatives is highly similar (Figure 3A). In the
case of the M2 receptor, bitopic ligands exhibit a fixed position
of the orthosteric moiety, which directs the positioning of the
allosteric building blocks. Interestingly, our data strongly
suggests the opposite for the M1 receptor (Supporting
Information Figure S5).54 Since BQCAd is very specific for
the M1 allosteric vestibule, it serves as an anchoring point,
which controls the positioning of the linker and thereby the
position of the orthosteric moiety in the orthosteric binding
site.
With regard to the orthosteric binding pocket, the essential
interaction responsible for receptor activation is the charge
interaction with D1053.32.55 The positive charge is additionally
surrounded by aromatic residues of the tyrosine lid (Y7.39 and
Y7.43), forming cation−π interactions. Since the tyrosine lid is
flexible to a certain extent and the charge interaction with
D1053.32 is not restricted to a distinct geometric position, the
position of the positive charge of the ammonium group shows
some variance (Figure 3B). Due to the flexibility of the alkyl
linker, this essential charge interaction can be observed for all
studied bitopic ligands. Both the alkyl linker length and the
type of the orthosteric building block control the location of
the ammonium group. This might also explain why there is no
direct pharmacological correlation between bitopic ligands and
their purely orthosteric building blocks (Figures 1 and 2).
Since the binding mode is mainly determined by the BQCAd
moiety and the linker length, the orthosteric building block
cannot necessarily build the same interactions as the purely
orthosteric ligands themselves. Interestingly, the compound
series with the smallest known orthostere (TMA) shows
robust G protein activation, which suggests that only the
charge interaction is crucial for G protein activation. Given that
5-C8 shows the highest potency with regard to G protein
activation, we analyzed its receptor−ligand interaction by using
dynamic pharmacophores.56 The initial binding mode of 5-C8
and the respective interaction pattern were conserved over 250
ns of MD simulation (Figure 3C). The largest movement was
observed for the benzyl ring, which shows a more frayed
distribution of its non-polar contacts, but this movement
occurred at the very beginning of the trajectory. The dynamic
interaction pattern indicates a key role of Y179 in the second
extracellular loop (ECL2) and W4007.35 for hosting the
BQCAd moiety in the allosteric vestibule of the M1 receptor.
This result is in accordance with previous mutational studies
that highlight key residues for allosteric modulation at the M1
receptor.57−59 Interestingly, the same epitopes have also been
shown to control shape and ligand binding properties of the
extracellular binding site of the M2 receptor.56,60 Since we
observed a surprisingly high potency (e.g., 4-C4) or high
efficacy (e.g., 1-C4) for some compounds of the C4 series, we
hypothesize that these bitopic ligands might show multiple
binding modes as previously reported for some bitopic
muscarinic agonists.61
In conclusion, we have presented a novel set of BQCAd-
based bitopic M1 receptor agonists comprising five different
orthosteric agonists and alkyl linkers of varying lengths. All
bitopic ligands are agonists with regard to G protein activation
with efficacies ranging from partial to full agonism. On the
other hand, only three ligands, i.e., 1-C6, 1-C8, and 3-C8, were
able to efficiently recruit β-arrestin in the concentration range
sufficient for G protein activation. Molecular modeling studies
demonstrate that the overall binding mode of the bitopic
ligands is mainly determined by the position of the allosteric
BQCAd moiety. Hence, the ligands are “hung up” in the
Figure 3. Proposed binding modes for BQCAd-derived bitopic ligands at the M1 receptor indicate a distinct position of the allosteric BQCAd
moiety, whereas the positioning of the orthosteric building block is more diverse. (A) Superimposition of 1-C8 (green), 2-C8 (salmon), 3-C8
(blue), 4-C8 (dark gray), and 5-C8 (light grey) bound to the M1 receptor. (B) Superimposition of 5-C8 (light gray) and 5-C4 (yellow) bound to
the M1 receptor. (C) Dynamic interaction pattern of 5-C8, the most potent compound from the series with the minimal orthosteric building block,
derived from a 250 ns MD simulation. Yellow point clouds indicate non-polar contacts, the blue point cloud shows positive ionizable centers, the
purple point cloud shows aromatic interactions, and the red point clouds indicate hydrogen bond acceptors. Next to the point clouds, the
occurrence frequency and the involved residues are indicated.
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allosteric vestibule of the receptor, and the orthosteric moieties
“dangle” into the orthosteric binding site. This may result in a
situation where the orthosteric moieties of the bitopic ligands
adopt different binding poses as their parent orthosteres alone.
This would be in line with our experimental data showing that
several bitopic ligands are less potent and efficacious than their
respective orthosteric agonists. Moreover, shrinking the
orthosteric moiety down to the essential ammonium ion (as
in TMA, 5-Cn series) is sufficient to induce a potent and
efficacious G protein response; however, these bitopic ligands
fail to stimulate β-arrestin recruitment. It seems that a quite
voluminous molecular portion having a higher molecular
weight than that originating from the quaternary ammonium
head at the orthosteric site is one of the prerequisite for β-
arrestin 2 recruitment. The finding that the ligands’ binding
poses are determined by their allosteric building block may
point toward a higher receptor subtype selectivity than that of
other bitopic ligands.62 Therefore, the whole set of bitopic
ligands represents a useful toolbox of compounds to outline
the chemical requirements for modulating the degree of β-
arrestin recruitment and G protein activation and thus,
facilitating the development of efficacious and selective drug
candidates for the treatment of diseases such as Alzheimer and
schizophrenia.
■ MATERIALS AND METHODS
Materials. A Chinese hamster ovary (CHO) cell line stably
expressing hM1 was obtained from Wyeth Research (Prince-
ton, NJ). 96-Well round-bottom and white 96-well plates were
purchased from ThermoFisher and from Greiner Bio One,
Germany. Dulbecco’s modified Eagle’s medium (DMEM) and
phosphate-buffered saline (PBS) were from Sigma (Schnell-
dorf, Germany). Leibovitz’s L-15 medium (L-15) and Hank’s
balanced salt solution (HBSS) were from ThermoFisher
(Dreieich, Germany). Fetal calf serum (FCS), trypsin, and
geneticin (G418) were from Merck Biochrom (Berlin,
Germany). D-Luciferin was purchased as a potassium salt
from Pierce (ThermoFisher, Dreieich, Germany) and was
dissolved in HBSS at a concentration of 400 mM. Puromycin
was obtained from Invivogen (Toulouse, France). [3H]N-
Methylscopolamine, 250 μCi (9.25 MBq), was purchased from
PerkinElmer (Rodgau, Germany) and polyethylenimine
solution (1%, PEI) from Sigma (Schnelldorf, Germany). For
chromatographic applications (HPLC, LC−MS), deionized
water produced by means of a Milli-Q system (Merck,
Darmstadt, Germany) was used. HPLC grade and LC−MS
grade solvents were from Sigma-Aldrich (Munich, Germany).
Unless stated otherwise, all chemicals were purchased from
Sigma-Aldrich (Schnelldorf, Germany), VWR (Darmstadt,
Germany), and TCI (Eschborn, Germany) and were used
without prior purification.
General Medicinal Chemistry Methods. 1H (400.132
MHz) and 13C (100.613 MHz) NMR spectra were recorded
using a Bruker AV 400 NMR spectrometer (Bruker Biospin,
Ettlingen, Germany). As an internal standard, the signals of the
deuterated solvents were used (DMSO-d6:
1H 2.5 ppm, 13C
39.52 ppm; CDCl3:
1H 7.26 ppm, 13C 77.16 ppm).
Abbreviations for data quoted are s, singlet; d, doublet; t,
triplet; q, quartet; m, multiplet; b, broad; dd, doublet of
doublets; dt, doublet of triplets; tt, triplet of triplets; and tq,
triplet of quartets. Coupling constants (J) are given in Hz. The
NMR signals were assigned polarization transfer experiments
(DEPT) and two-dimensional experiments, such as 1H-1H
correlation (COSY) and 1H-13C-proton-carbon heteronuclear
correlation (HMQC, HMBC). TLC analyses were performed
on silica gel 60 F254, C18 silica-coated aluminum panels
ALUGRAM RP-18W/UV254 and on precoated TLC plates
Alox-25/UV254 (Macherey-Nagel, Düren, Germany); the
detection was made using UV light at 254 nm, intrinsic
fluorescence at 366 nm or with ethanolic KMnO4, Dragendorff
reagent, or phosphomolybdic acid ethanolic solution. For
classical purification, column chromatography was performed
using silica gel with a grain size of 63−200 μm (Merck,
Darmstadt, Germany). Flash chromatography on a puri-
Flash430 system (Interchim, Montluc ̧on, France) was
performed using prepacked columns (Interchim, Montluco̧n,
France) with silica gel filling (particle size, 30 or 50 μm) for
the normal phase or with C18-silica gel filling (particle size, 15
μm) for the reverse phase. The detection was carried out by
means of a UV detector and an evaporative light scattering
detector (ELSD). Microwave-assisted reactions were carried
out using an MLS-rota PREP or synthWAVE instruments
(Milestone). The LC−MS analyses of all the test compounds
were performed using a Shimadzu LC-MS-2020 mass
spectrometer (Shimadzu Deutschland GmbH, Duisburg,
Germany) containing a DGU-20A3R degassing unit, an
LC20AB liquid chromatograph, and SPD-20A UV/Vis
detector, and an LC/MSD ion trap (Agilent Technologies,
Waldbronn, Germany) connected to an Agilent 1100 modular
system. A Synergi Fusion-RP (150 mm × 4.6 mm, i.d., 4 μm;
Phenomenex Ltd., Aschaffenburg, Germany) column and a
gradient consisting of solvent A, water with 0.1% formic acid,
and solvent B, MeOH with 0.1% formic acid, were used.
Solvent B was increased from 0 to 90% in 13 min then
decreased to 5% in 1 min and 5% for 4 min. The method was
run with a flow rate of 1.0 mL/min and UV detection at 254
nm. All compounds were found to have a purity of ≥95%.
Mass spectra were recorded in ESI-positive mode, and the data
are reported as the mass-to-charge ratio (m/z) of the
corresponding positively charged molecular ions. Detailed
syntheses and spectral data of intermediate and target
compounds are reported in the Supporting Information
(Data S1).
Cell Culture. Chinese hamster ovary cells (CHO) stably
expressing the hM1 receptor (CHO-hM1 cells) were cultured
in Ham’s nutrient mixture F-12 (HAM- F12) supplemented
with 10% (v/v) FCS (FCS), 100 U/mL penicillin, 100 μg/mL
streptomycin, 0.2 mg/mL G418, and 2 mM L-glutamine at 37
°C in a 5% CO2-humidified atmosphere. HEK293T cells stably
cotransfected with the human M1 receptor and the Gαq-PLC-
β3 sensor51 were kindly provided by Timo Littmann
(University of Regensburg). Cells were cultured in DMEM
containing 10% FCS (full medium) at 37 °C in a water-
saturated atmosphere containing 5% CO2 as reported
previously.51 HEK293T cells for BRET assays were cultured
in a DMEM high-glucose medium containing 10% FCS, 2 mM
glutamine, 500 units × mL−1 penicillin, and 0.5 mg × mL−1
streptomycin.
Split-Luciferase Bioluminescence Assay. HEK293T
cells stably cotransfected with the human M1 receptor and
the Gαq-PLC-β3 sensor51 were detached from a 75 cm2 flask
by trypsinization and centrifuged (700g for 5 min). The pellet
was resuspended in an assay medium consisting of L-15 with
5% FCS, and the density of the suspension was adjusted to
1.25 × 106 cells/mL. Then, 80 μL of this suspension was
seeded into each well of a 96-well plate, and the plate was
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subsequently incubated at 37 °C in a humidified atmosphere
(without additional CO2) overnight. On the next day, 10 μL of
10 mM D-luciferin (Pierce) was added to the cells, and the
plate was transferred into a prewarmed microplate lumines-
cence reader (Mithras LB 940 Multimode Microplate Reader,
Berthold Technologies, Bad Wildbad, Germany). The cells
were allowed to equilibrate inside the reader for 10 min before
basal luminescence was determined by recording luminescence
for the entire plate ten times with an integration time of 0.5 s
per well. In the meantime, serial dilutions of agonists were
prepared. The resulting solutions were also prewarmed to 37
°C and subsequently added to the cells. Thereafter,
luminescence was recorded for 15 plate repeats amounting
to a time period of 20 min. Negative controls (solvent) and
positive controls (reference full agonist, carbachol (hM1R))
eliciting a maximal response (100%) were included for
subsequent normalization of the data. After acquisition of the
data, the peak luminescence intensities obtained after
stimulation were used for quantitative analysis using GraphPad
Software (San Diego, CA, USA).
β-Arrestin 2 Recruitment Assay. β-Arrestin 2 recruit-
ment was determined by measuring BRET by using the
NanoBRET system.63 BRET was measured between a full
length human M1 receptor N-terminally carrying a FLAG-tag
and C-terminally carrying a nanoluciferase. The β-arrestin 2
was N-terminally modified with a HALO-tag and labeled with
a HALO-618 fluorescent ligand (Promega, Mannheim,
Germany). Therefore, 1 × 106 HEK293T cells were seeded
in a 6 cm dish and after 20 h transiently transfected with 1 μg
of the receptor, 2 μg of β-arrestin 2, and 1 μg of human GRK2
with the Effectene transfection reagent in accordance to the
user manual. Twenty hours after transfection, cells were
transferred from 6-well plates to 96-well plates. Cells were
counted, and 20,000 cells per well were seeded into white 96-
well plates (Brand GmbH & Co. KG, Wertheim, Germany).
The next day, BRET was measured using the Synergy Neo2
Hybrid Multi-Mode Reader (BioTek Instruments GmbH, Bad
Friedrichshall, Germany), and the BRET ratio was corrected
against buffer conditions. The highest ligand concentration
tested was 100 μM due to limited solubility in the buffer used
for BRET assays.
Computational Analysis Methods. All receptor-ligand
docking experiments were carried out with CCDC’s software
GOLD version 5.1.64 A previously reported active homology
model of the M1 receptor, which is in accordance with the
available active M1 receptor cryo-EM structure, was used for
docking.60 All residues of the receptor core region and the
extracellular loop regions were defined as potential binding
sites. Default settings were applied for receptor−ligand docking
using GoldScore as a primary scoring function. All docking
poses and receptor−ligand interactions were analyzed with
LigandScout 4.2,65 using a 3D pharmacophore approach. The
molecular dynamics simulations were carried out on GPUs
(Nvidia RTX 2080 Ti) at the Freie Universitaẗ Berlin with
Desmond 2018-3 following the previously published proce-
dure.56 Subsequently, the MD trajectories were analyzed with
software VMD66 and a dynamic pharmacophore approach
(dynophores) implemented in the LigandScout frame-
work.56,65,67
Data Treatment. The binding data from individual
experiments were analyzed by computer-aided nonlinear
regression analysis using Prism 5 (GraphPad Software, San
Diego, CA, USA). All sigmoidal concentration-response curves
were obtained by fitting three-parameter (Hill slope con-
strained to 1) nonlinear regression curves (GraphPad Prism,
San Diego, CA, USA). The BRET raw data were analyzed and
corrected in Excel (Microsoft Corporation, WA, USA) and
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